Skip to content

Pre-Tax Income at other companies

Eli Lilly logo
Eli LillyLLY
$8.85B+156%
Arrowhead Research logo
Arrowhead ResearchARWR
-$137.57M-137%
Alkermes logo
AlkermesALKS
-$61.93M-343%
TG Therapeutics logo
TG TherapeuticsTGTX
$20.36M+272%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$246.8M+1,579%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$6.64B+77.3%
Enterprise value$6.69B+78.4%
P/S30.6×+3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rhythm Pharmaceuticals, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rhythm Pharmaceuticals, Inc.'s pre-tax income?
Rhythm Pharmaceuticals, Inc. (RYTM) reported pre-tax income of -$55.09M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s pre-tax income decreased by 11.5% year-over-year, from -$49.42M to -$55.09M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s pre-tax income?
Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s pre-tax income has grown at a 3.2% compound annual growth rate (CAGR), from -$184.11M to -$196.04M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.